NCT00625131

Brief Summary

This study seeks to evaluate the relationship between PTSD, abstinence, and factors associated with relapse in the context of a randomized, clinical smoking cessation trial.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
87

participants targeted

Target at P75+ for early_phase_1

Timeline
Completed

Started May 2008

Longer than P75 for early_phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 19, 2008

Completed
9 days until next milestone

First Posted

Study publicly available on registry

February 28, 2008

Completed
2 months until next milestone

Study Start

First participant enrolled

May 1, 2008

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2013

Completed
1.7 years until next milestone

Results Posted

Study results publicly available

November 20, 2014

Completed
Last Updated

November 20, 2014

Status Verified

November 1, 2014

Enrollment Period

4.8 years

First QC Date

February 19, 2008

Results QC Date

October 28, 2014

Last Update Submit

November 12, 2014

Conditions

Keywords

Stress Disorders, PosttraumaticTobacco Use Disorder

Outcome Measures

Primary Outcomes (1)

  • Smoking Abstinence, Self-reported

    Number of participants by group reporting 1 week of self-reported abstinence in the week prior to Session 12 at six weeks post-treatment

    Week prior to Session 12 at 6 weeks post-treatment

Secondary Outcomes (2)

  • Carbon Monoxide Monitoring

    Session 12 (6 weeks post-treatment)

  • Smoking Craving

    Daily between visits 2-12

Study Arms (2)

Active Nicotine Patch Group

ACTIVE COMPARATOR

Transdermal nicotine patch

Drug: NicotineBehavioral: Cognitive Behavioral Therapy for Smoking CessationDrug: Bupropion Sustained Release (SR)

Placebo Patch Group

PLACEBO COMPARATOR

Transdermal placebo patch

Behavioral: Cognitive Behavioral Therapy for Smoking CessationDrug: Bupropion Sustained Release (SR)Drug: Placebo patch

Interventions

Delivered through transdermal nicotine patch

Active Nicotine Patch Group

Manualized protocol for CBT in smoking cessation

Also known as: CBT
Active Nicotine Patch GroupPlacebo Patch Group

Antidepressant

Also known as: Zyban, Wellbutrin
Active Nicotine Patch GroupPlacebo Patch Group

Pre-treatment placebo transdermal patch

Placebo Patch Group

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Smokers who smoke 10 or more cigarettes per day in the past year;
  • years old;
  • English speakers;
  • medically stable;
  • stable on current medication regimen

You may not qualify if:

  • Pregnant women excluded;
  • participants with organic mental disorder, schizophrenia, bipolar disorder, lifetime but not current PTSD, current substance abuse or dependence;
  • medical conditions contraindicated with nicotine replacement therapy;
  • use other forms of nicotine (cigars, nicotine gum, etc.)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

VA Medical Center, Durham

Durham, North Carolina, 27705, United States

Location

Related Publications (1)

  • Dedert EA, Dennis PA, Calhoun PS, Dennis MF, Beckham JC. A Randomized Clinical Trial of Nicotine Preloading for Smoking Cessation in People with Posttraumatic Stress Disorder. J Dual Diagn. 2018 Jul-Sep;14(3):148-157. doi: 10.1080/15504263.2018.1468947. Epub 2018 Oct 10.

MeSH Terms

Conditions

Stress Disorders, Post-TraumaticTobacco Use Disorder

Interventions

NicotineCognitive Behavioral TherapyBupropion

Condition Hierarchy (Ancestors)

Stress Disorders, TraumaticTrauma and Stressor Related DisordersMental DisordersSubstance-Related DisordersChemically-Induced Disorders

Intervention Hierarchy (Ancestors)

Solanaceous AlkaloidsAlkaloidsHeterocyclic CompoundsPyridinesHeterocyclic Compounds, 1-RingBehavior TherapyPsychotherapyBehavioral Disciplines and ActivitiesPropiophenonesKetonesOrganic Chemicals

Results Point of Contact

Title
Angela Kirby, MS; Regulatory Coordinator
Organization
VA Medical Center, Durham, NC

Study Officials

  • Jean C. Beckham, PhD

    VA Medical Center, Durham

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 19, 2008

First Posted

February 28, 2008

Study Start

May 1, 2008

Primary Completion

March 1, 2013

Study Completion

March 1, 2013

Last Updated

November 20, 2014

Results First Posted

November 20, 2014

Record last verified: 2014-11

Locations